Subscribe to Newsletter

Carl Regillo

Director, Retina Service, Wills Eye Hospital, Professor of Ophthalmology at Thomas Jefferson University, Philadelphia, Pennsylvania, USA

The biggest breakthrough in retina…

It has to be anti-VEGF therapy, and small incision vitrectomy. The former has revolutionized the outcomes of the most common, blinding retinal disease, whereas the latter has made vitreoretinal surgery safer and more efficient.

Your predictions for the field…

We are likely to see effective treatments for advanced dry AMD and GA, as well as the use of gene therapy to treat common retinal conditions.

A technology you would not have been able to live without over the past 10 years…

That would definitely be OCT.

The biggest challenge facing your field in 2022 – and beyond?

The burden of ongoing frequent intravitreal injections for patients.

If you weren’t an ophthalmologist…

I would have pursued interventional cardiology.

Part of the Power List 2020

Find out more

From ocular oncology to tackling neglected diseases, our 2020 Power Listers are making their mark on ophthalmology – and beyond.

Go to The Power List 2020

Part of the Power List 2018

100 reasons to be proud

This is the third time we have tried to map the Top 100 most influential people in the world of ophthalmology. The list includes surgeons, scientists, engineers, CEOs and more, and each one of them has been voted for by you, our readers.

Go to The Power List 2018

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: